{"schema_version":"secwatch.filing_event.v1","accession":"0001640266-26-000007","form_type":"8-K","ticker":"VYGR","cik":"0001640266","company_name":"Voyager Therapeutics, Inc.","filed_at":"2026-08-06T20:03:23+00:00","discovered_at":"2026-08-06T20:05:01.339228+00:00","generated_at":"2026-08-06T20:05:31.396155+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Voyager Q2 net loss narrows to $24.5M; cash $148.8M, runway into 2028; tau programs on track for Q4 data","bullets":["Net loss $24.5M in Q2 2026 vs $33.4M in Q2 2025; collaboration revenue $3.2M (down from $5.2M).","Cash, equivalents, and marketable securities $148.8M as of June 30, 2026; expected to fund operations into 2028.","VY7523 tau PET imaging data expected Q4 2026; VY1706 tau gene therapy IND cleared, dosing expected Q4 2026.","Neurocrine partner intends to initiate NBIB-223 trial for Friedreich's ataxia in H2 2026 pending FDA IND clearance.","R&D expenses $22.0M (down from $31.3M) and G&A $7.5M (down from $10.5M) due to prioritization and restructuring."],"urls":{"canonical":"https://secwatch.observer/filing/0001640266-26-000007","json":"https://secwatch.observer/filing/0001640266-26-000007.json","markdown":"https://secwatch.observer/filing/0001640266-26-000007.md","text":"https://secwatch.observer/filing/0001640266-26-000007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1640266/000164026626000007/0001640266-26-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1640266/000164026626000007/vygr-20260806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T20:05:31.396155+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}